Wall Street was not surprised on 28 May by the US FDA granting Alexion Pharmaceuticals' investigational hypophosphatasia (HPP) drug asfotase alfa (ENB-0040) a breakthrough therapy designation, given the high unmet medical need for the potentially life-threatening, ultra-rare metabolic genetic disease.
Unsurprising FDA 'breakthrough' designation for Alexion's hypophosphatasia drug
Wall Street was not surprised on 28 May by the US FDA granting Alexion Pharmaceuticals' investigational hypophosphatasia (HPP) drug asfotase alfa (ENB-0040) a breakthrough therapy designation, given the high unmet medical need for the potentially life-threatening, ultra-rare metabolic genetic disease.
More from Musculoskeletal
More from Therapeutic Category
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.